Photodynamic Therapy With Visudyne for Human Retinoblastoma: A Preliminary Study
- Conditions
- Retinoblastoma
- Interventions
- Drug: photodynamic therapy
- Registration Number
- NCT04429139
- Lead Sponsor
- Sun Yat-sen University
- Brief Summary
To study the effectiveness and safety profiles of photodynamic therapy (PDT) for the treatment of human retinoblastoma.
- Detailed Description
Retinoblastoma is the commonest primary intraocular malignancy in infancy and early childhood. Ophthalmologist are trying to seek other more safe and effective treatment modalities to well control the tumor and preserve the visual function. Photodynamic therapy (PDT) is a potentially therapeutic approach for retinoblastoma which has been underestimated. In this study, we are gonging to investigate the the effectiveness and safety profiles of photodynamic therapy (PDT) for the treatment of human retinoblastoma.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 8
- patients with intraocular retinoblastoma of Group A-D
- (1) patients with intraocular retinoblastoma of group E; (2) patients with extraocular spread; (3); media opacities such as corneal opacity, significant cataract, or vitreous hemorrhage obscuring fundus examination; (4) patients who were allergic to verteporfin or other benzoporphyrin derivatives.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description PDT treatment group photodynamic therapy All the patients received once PDT with Visudyne® as the initial treatment. Rescue treatment with systemic chemotherapy would be given to patients if tumors were insensitive to PDT treatment, the tumors became larger, or disease relapse.
- Primary Outcome Measures
Name Time Method eye enucleation 3 years the rate of eye enucleation of patients with retinoblastoma in different groups
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Kunbei Lai
🇨🇳Guangzhou, Guangdong, China